Investors in Hyphens Pharma International (Catalist:1J5) Have Seen Favorable Returns of 75% Over the Past Five Years

Yahoo FinanceApr 23 18:06 ET

Hyphens Pharma's Attributable Profit Narrows in 2023

Hyphens Pharma (SGX:1J5) booked a lower attributable profit to equity holders of SG$8.6 million for the year ended Dec. 31, 2023, compared with SG$11.4 million in the year-ago period, according to a f

MT NewswiresApr 9 02:16 ET

Huationg Global CEO Increases Interest to 7.75%

Huationg Global CEO increases interest to 7.75%INSTITUTIONS were net buyers of Singapore stocks over the four trading sessions until Apr 4 inclusive, with S$49 million of net institutional inflow, as

Singapore ExchangeApr 7 21:34 ET

Hyphens Pharma Buys Back Shares

Hyphens Pharma International (SGX:1J5) bought back 471,200 shares in the open market on Tuesday, its first purchase since the board approved a buyback program of up to 30.9 million shares last year, a

MT NewswiresApr 2 22:56 ET

CGS-CIMB Adjusts Hyphens Pharma's Price Target to SG$0.35 From SG$0.32, Keeps at Add

02:34 AM EDT, 03/15/2024 (MT Newswires) -- CGS-CIMB Adjusts Hyphens Pharma's Price Target to SG$0.35 From SG$0.32, Keeps at Add Price (SGD): S$0.29, Change: S$0.00, Percent Change: 0.00%

MT NewswiresMar 15 02:34 ET

Hyphens Pharma Obtains License to MC2's Psoriasis Cream

Hyphens Pharma International (SGX:1J5) obtained an exclusive license to register and commercialize MC2 Therapeutics' Wynzora plaque psoriasis cream in all 10 member countries of the Association of Sou

MT NewswiresMar 13 01:47 ET